Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
World J Urol. 2021 Jun;39(6):1757-1768. doi: 10.1007/s00345-020-03436-0. Epub 2020 Sep 29.
We conducted a systematic review and meta-analysis to assess the available literature regarding the surgical and oncologic outcomes of patients undergoing salvage radical cystectomy (SV-RC) for recurrence or failure of bladder sparing therapy (BST) for muscle-invasive bladder cancer (MIBC).
We searched MEDLINE (PubMed), EMBASE and Google Scholar databases in May 2020. We included all studies of patients with ≥ cT2N0/xM0 bladder cancer that were eligible for all treatment modalities at the time of treatment decision who underwent BST including radiotherapy (RTX). A meta-analysis was conducted to calculate the pooled rate of several variables associated with an increased need for SV-RC. Study quality and risk of bias were assessed using MINORS criteria.
73 studies comprising 9110 patients were eligible for the meta-analysis. Weighted mean follow-up time was 61.1 months (range 12-144). The pooled rate of non-response to BST and local recurrence after BST, the two primary reasons for SV-RC, was 15.5% and 28.7%, respectively. The pooled rate of SV-RC was 19.2% for studies with a follow-up longer than 5 years. Only three studies provided a thorough report of complication rates after SV-RC. The overall complication rate ranged between 67 and 72% with a 30-day mortality rate of 0-8.8%. The pooled rates of 5 and 10-year disease-free survival after SV-RC were 54.3% and 45.6%, respectively.
Approximately one-fifth of patients treated with BST with a curative intent eventually require SV-RC. This procedure carries a proportionally high rate of complications and is usually accompanied by an incontinent urinary diversion.
我们进行了一项系统评价和荟萃分析,以评估有关挽救性根治性膀胱切除术(SV-RC)治疗肌层浸润性膀胱癌(MIBC)患者接受保膀胱治疗(BST)复发或失败的现有文献。
我们于 2020 年 5 月检索了 MEDLINE(PubMed)、EMBASE 和 Google Scholar 数据库。我们纳入了所有在治疗决策时符合所有治疗方式标准且接受 BST(包括放疗(RTX))的≥cT2N0/xM0 膀胱癌患者的研究。我们进行了荟萃分析,以计算与 SV-RC 需求增加相关的几个变量的汇总率。使用 MINORS 标准评估研究质量和偏倚风险。
73 项研究纳入了 9110 名患者进行荟萃分析。加权平均随访时间为 61.1 个月(范围 12-144)。BST 无反应和 BST 后局部复发(SV-RC 的两个主要原因)的汇总率分别为 15.5%和 28.7%。随访时间超过 5 年的研究中,SV-RC 的汇总率为 19.2%。只有 3 项研究提供了 SV-RC 后并发症发生率的详细报告。总体并发症发生率在 67%至 72%之间,30 天死亡率为 0-8.8%。SV-RC 后 5 年和 10 年无病生存率的汇总率分别为 54.3%和 45.6%。
大约五分之一接受保膀胱治疗且有治愈意图的患者最终需要接受 SV-RC。该手术具有较高的并发症发生率,通常伴有不可控的尿失禁转流。